Preliminary results on long-term follow-up of systemic sclerosis patients under extracorporeal photopheresis.
Extracorporeal photopheresis
extracorporeal photochemotherapy
scleroderma
survival
systemic sclerosis
Journal
The Journal of dermatological treatment
ISSN: 1471-1753
Titre abrégé: J Dermatolog Treat
Pays: England
ID NLM: 8918133
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
pubmed:
5
5
2021
medline:
12
7
2022
entrez:
4
5
2021
Statut:
ppublish
Résumé
Extracorporeal photopheresis (ECP) has been considered for treatment of patients with systemic sclerosis (SSc). To study the 12-month effects of ECP on laboratory parameters and evaluate the SSc-related long-term survival. 59 SSc patients who had received at least 6 ECP cycles were included. Lab parameters were assessed at baseline (ECP naïve), after 6 months, and after 12 months. 20-year follow-up data were collected for all patients. 31 (59/52.5%) patients presented with elevated serum III procollagen (sPIIINP) levels at baseline which significantly declined after 6- and 12-month ECP. Total lymphocyte counts as well as circulating immune complexes (CICs) significantly decreased after 12-months ECP. On long-term follow-up, patients had received a median of 37.5 (6-167) ECP cycles over a median period of 64 (6-281) months. 20-year follow-up revealed only 8 (59/13.6%) SSc-related deaths and 51 (59/86.4%) survivors. One-year ECP induces changes in lab parameters, such as sPIIINP, CICs, and lymphocyte counts, which have previously been implicated in the pathogenesis of SSc. More importantly, our data reveal, for the first time, that ECP-treated SSc patients appear to have extremely favorable 20-year survival rates compared to other SSc cohorts reported in the literature.
Sections du résumé
BACKGROUND
UNASSIGNED
Extracorporeal photopheresis (ECP) has been considered for treatment of patients with systemic sclerosis (SSc).
OBJECTIVES
UNASSIGNED
To study the 12-month effects of ECP on laboratory parameters and evaluate the SSc-related long-term survival.
METHODS
UNASSIGNED
59 SSc patients who had received at least 6 ECP cycles were included. Lab parameters were assessed at baseline (ECP naïve), after 6 months, and after 12 months. 20-year follow-up data were collected for all patients.
RESULTS
UNASSIGNED
31 (59/52.5%) patients presented with elevated serum III procollagen (sPIIINP) levels at baseline which significantly declined after 6- and 12-month ECP. Total lymphocyte counts as well as circulating immune complexes (CICs) significantly decreased after 12-months ECP. On long-term follow-up, patients had received a median of 37.5 (6-167) ECP cycles over a median period of 64 (6-281) months. 20-year follow-up revealed only 8 (59/13.6%) SSc-related deaths and 51 (59/86.4%) survivors.
CONCLUSIONS
UNASSIGNED
One-year ECP induces changes in lab parameters, such as sPIIINP, CICs, and lymphocyte counts, which have previously been implicated in the pathogenesis of SSc. More importantly, our data reveal, for the first time, that ECP-treated SSc patients appear to have extremely favorable 20-year survival rates compared to other SSc cohorts reported in the literature.
Identifiants
pubmed: 33944664
doi: 10.1080/09546634.2021.1925078
doi:
Substances chimiques
Antigen-Antibody Complex
0
Procollagen
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM